Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

L6668

Sigma-Aldrich

Lercanidipine hydrochloride

≥98% (HPLC), powder, dihydropyridine calcium-channel blocker

Synonym(s):

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester 3,5-pyridinedicarboxylic acid hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C36H41N3O6 · HCl
CAS Number:
132866-11-6
Molecular Weight:
648.19
MDL number:
MFCD07773089
UNSPSC Code:
12352200
PubChem Substance ID:
24724527
NACRES:
NA.77

product name

Lercanidipine hydrochloride, ≥98% (HPLC)

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated
protect from light

color

yellow

originator

Forest Labs

storage temp.

2-8°C

SMILES string

O=C(OC)C1=C(C)NC(C)=C(C(OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)=O)C1C4=CC([N+]([O-])=O)=CC=C4.Cl

InChI

1S/C36H41N3O6.ClH/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27;/h7-19,22,30,33,37H,20-21,23H2,1-6H3;1H

InChI key

WMFYOYKPJLRMJI-UHFFFAOYSA-N

Biochem/physiol Actions

Lercanidipine hydrochloride is a L-type (Cav1.2b) vascular channel antagonist; L-type (Cav1.2a) cardiac channel agonist voltage-dependent and highly lipophylic compound, which exhibits a slower onset and longer duration of action than other calcium channel antagonists; an antihypertensive agent in patients with mild-to-moderate hypertension; more vasoselective than lacidipine and amlodipine.

Features and Benefits

This compound was developed by Forest Labs. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Ketoprofen ≥98% (TLC)

Sigma-Aldrich

K1751

Ketoprofen

Yuezhang Chen et al.
Molecular medicine reports, 16(4), 4545-4552 (2017-08-30)
Previous studies have demonstrated that lercanidipine, a calcium channel blocker, may protect against cardiac hypertrophy; however, the underlying mechanisms remain unclear. In the present study, the effects of lercanidipine on hypertrophy and the mechanisms involved were investigated. Cardiomyocytes isolated from
Jürgen Scholze et al.
Expert opinion on pharmacotherapy, 12(18), 2771-2779 (2011-10-18)
A fixed-dose combination (FDC) of enalapril and lercanidipine has been shown to be effective and safe in reducing blood pressure in randomized clinical trials. This study aims to determine effectiveness and safety in daily practice. This was a prospective, open-label
P-J Hsiao et al.
Clinical nephrology, 74(3), 217-222 (2010-09-24)
Lercanidipine, a novel dihydropyridine calcium channel antagonist, has been reported to cause sterile cloudy effluent in patients on continuous ambulatory peritoneal dialysis (CAPD). The purpose of the study was to evaluate the incidence and clinical course of cloudy effluent associated
Nitin Parmar et al.
Colloids and surfaces. B, Biointerfaces, 86(2), 327-338 (2011-05-10)
The present study deals with the development and characterization of self-nanoemulsifying drug delivery system (SNEDDS) to improve the oral bioavailability of poorly soluble third generation calcium channel blocker lercanidipine (LER). Solubility of the LER was estimated in various oils, cosurfactants
Arrigo F G Cicero et al.
Clinical and experimental hypertension (New York, N.Y. : 1993), 34(2), 113-117 (2011-10-05)
The aim of this study is to assess the blood pressure (BP) and metabolic effects of lercanidipine when combined with other classes of first-line antihypertensive drugs in day-to-day clinical practice. For this study, we consecutively enrolled 162 patients with uncomplicated
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service